High Plasma Thrombomodulin Level is Associated with a Decreased Risk of Cognitive Impairment after Ischemic Stroke

Yu He,Xinyue Chang,Yi Liu,Jiawen Fei,Xiaoli Qin,Beiping Song,Quan Yu,Mengyao Shi,Daoxia Guo,Jing Chen,Aili Wang,Tan Xu,Jiang He,Yonghong Zhang,Zhengbao Zhu
DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.108172
IF: 2.677
2024-01-01
Journal of Stroke and Cerebrovascular Diseases
Abstract:Background Thrombomodulin, a thrombin receptor with anticoagulant, anti-inflammatory, and cytoprotective properties, has been suggested to play a pivotal role in ischemic stroke. However, the association of plasma thrombomodulin with post-stroke cognitive impairment (PSCI) remains unclear. We aimed to prospectively investigate the associations of plasma thrombomodulin with PSCI among ischemic stroke patients in a multicenter cohort study. Methods We measured plasma thrombomodulin levels at baseline among 615 ischemic stroke patients from a preplanned ancillary study of the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). We used Montreal Cognitive Assessment (MoCA) to evaluate cognitive function at 3-month follow-up after ischemic stroke, and PSCI was defined as MoCA score <23. Results Plasma thrombomodulin was inversely associated with PSCI, and the adjusted odds ratio of PSCI for the highest versus lowest quartile of thrombomodulin was 0.50 (95% CI: 0.28-0.92, Ptrend=0.026). Each standard deviation increment of log-transformed thrombomodulin was associated with a 23% (odds ratio: 0.77, 95% CI: 0.62-0.97, P=0.029) decreased risk of PSCI. In addition, plasma thrombomodulin could significantly improve the risk reclassification of PSCI beyond established risk factors (net reclassification index: 25.04%, 95% CI: 7.20%-42.87%, P=0.007; integrated discrimination improvement: 1.13%, 95% CI: 0.18%-2.09%, P=0.020). Conclusions High plasma thrombomodulin levels were associated with a decreased risk of PSCI among ischemic stroke patients. Our findings suggest that plasma thrombomodulin might be a predictive biomarker and potential therapeutic target for PSCI.
What problem does this paper attempt to address?